Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
1.970
-0.080 (-3.90%)
At close: Jun 27, 2025, 4:00 PM
2.030
+0.060 (3.05%)
After-hours: Jun 27, 2025, 7:20 PM EDT
Vistagen Therapeutics Employees
As of March 31, 2025, Vistagen Therapeutics had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 17 or 42.50% compared to the previous year.
Employees
57
Change (1Y)
17
Growth (1Y)
42.50%
Revenue / Employee
$8,526
Profits / Employee
-$902,070
Market Cap
57.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VTGN News
- 3 days ago - Vistagen Appoints Elissa Cote as Chief Corporate Development Officer - Business Wire
- 10 days ago - Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 16 days ago - Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 - Business Wire
- 26 days ago - Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year - Business Wire
- 4 weeks ago - Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - Business Wire
- 5 weeks ago - Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - Business Wire
- 2 months ago - Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - Business Wire